Immune Checkpoint Inhibitors
Monoclonal-antibody cancer therapies that block inhibitory immune checkpoints such as PD-1, PD-L1, or CTLA-4.
Core metadata
- ID: immuno_oncology_checkpoint_inhibitors
- Era: Modern
- First known date: 2011 (exact)
- Region: United States, Japan, Europe, and global oncology
- Review status: source_checked
- Maturity: established
Prerequisites
- Advanced Immunology (immunology_advanced)
- Monoclonal Antibodies (monoclonal_antibodies)
- Phase I-III Clinical Trials (phase_i_iii_clinical_trials)
Dependents
- None.
Fields
Field lanes
- Pharmaceuticals & Drug Development: Biologics & Vaccines
Node sources
- Immune Checkpoint Inhibitors (National Cancer Institute, 2026, official_agency) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 68%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| Monoclonal Antibodies (monoclonal_antibodies) | enabling | 68% | expert_inference | Monoclonal Antibodies provides a capability that enables this technology without being the only possible path. |
|
| Advanced Immunology (immunology_advanced) | enabling | 68% | expert_inference | Advanced Immunology provides a capability that enables this technology without being the only possible path. |
|
| Phase I-III Clinical Trials (phase_i_iii_clinical_trials) | enabling | 68% | expert_inference | Phase I-III Clinical Trials provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.